Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 12 500 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus PRADAXA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 12 500 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus PRADAXA.
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER vs PRADAXA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III (ATIII) and accelerates its inhibition of thrombin (factor IIa) and other serine proteases (factors Xa, IXa, XIa, XIIa) in the coagulation cascade, thereby preventing fibrin clot formation.
Direct thrombin inhibitor; binds reversibly to the active site of thrombin, preventing fibrinogen cleavage and subsequent thrombus formation.
Continuous IV infusion: Initial bolus 80 units/kg, then 18 units/kg/hour; subsequent dose adjusted based on aPTT. Typical infusion rate: 20,000–40,000 units/24 hours.
150 mg orally twice daily; for patients with CrCl 15-30 mL/min, 75 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is 1-2 hours at therapeutic doses, dose-dependent: 30-60 min after IV bolus of 25 U/kg, increasing to 1.5-2.5 hours after 400 U/kg. Prolonged in hepatic/renal impairment and pulmonary embolism. Clinical context: continuous infusion achieves steady-state after ~4-6 hours.
12–17 hours (terminal); prolonged to 18–35 hours in severe renal impairment (CrCl <30 mL/min); supports twice-daily dosing
Heparin is eliminated primarily via hepatic metabolism and renal excretion. Approximately 50% of a dose undergoes hepatic desulfation and depolymerization to form uroheparin, which is excreted in urine. Unchanged heparin is cleared renally via saturable, dose-dependent mechanisms. Biliary/fecal elimination is negligible (<5%).
Renal (80% unchanged); fecal/biliary (20% as inactive metabolites via P-glycoprotein-mediated secretion)
Category A/B
Category C
Anticoagulant
Anticoagulant